The COVID-19 outbreak created urgency for innovative diagnostic technologies. The triple-demic of COVID-19, RSV and influenza brought new challenges.

The “tripledemic” is not an official scientific term but it refers to the co-occurrence of RSV (respiratory syncytial virus), flu, and COVID-19 to the extent that it could overwhelm national healthcare systems. According to data from the Centers for Disease Control and Prevention in the United States, the number of reported cases started rising unusually early in 2022. Also in Europe, national authorities reported overcrowded hospital units. The situation is especially dangerous for elderly people, young children and people with compromised immune system.

While all three viruses can cause respiratory illnesses and exhibit similar symptoms, they remain independent viruses, and experts are concerned about coincidental waves or overlapping waves of each. It remains unclear how the viruses might interact with each other this winter so it’s crucial to continuously monitor the epidemiologic situation through centralized and point-of-care testing.

Parallel detection and differentiation of respiratory viruses seem to be gaining even more importance than during the COVID-19 pandemic.

By providing tools and solutions for multiplex analysis in various formats, SCIENION addresses the need for quick and reliable diagnostic tests to distinguish between COVID-19, RSV and influenza. Whether a simple test for home use or more sophisticated solutions to be used in doctors’ offices and clinical laboratories you can increase your manufacturing capacities with SCIENION’s assay development expertise and contract manufacturing facilities.